Cowen analyst Yaron Werber assumed coverage on Epizyme with an Outperform and $18 price target. The analyst noted that Tazemetostat is a de-risked asset with approval expected in 2020, and he anticipates $1B in peak sales, making this an “attractive overlooked opportunity.”
https://thefly.com/landingPageNews.php?id=2869879
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.